Cowen And Company, LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Cowen And Company, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 09, 2023	BUY	$87.74 - $117.27 $386,056 - $515,988	4,400 Added 44.0%	14,400 $1.4 Million
Q4 2022 Feb 09, 2023	BUY	$80.93 - $108.63 $809,300 - $1.09 Million	10,000 New	10,000 $1.03 Million
Q2 2022 Aug 05, 2022	SELL	$71.48 - $86.85 $2.68 Million - $3.26 Million	-37,500 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $1.55 Million - $1.93 Million	-20,800 Reduced 35.68%	37,500 $46,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $4.18 Million - $5.33 Million	58,300 New	58,300 $12,000
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $747,700 - $854,700	-10,000 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $377,550 - $423,950	-5,000 Reduced 33.33%	10,000 $12,000
Q1 2021 May 04, 2021	SELL	$74.73 - $90.69 $1.07 Million - $1.3 Million	-14,300 Reduced 48.81%	15,000 $20,000
Q4 2020 Feb 08, 2021	BUY	$72.61 - $90.2 $1.49 Million - $1.85 Million	20,500 Added 232.95%	29,300 $124,000
Q3 2020 Nov 03, 2020	BUY	$71.87 - $131.03 $632,456 - $1.15 Million	8,800 New	8,800 $29,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.